HTLV-I Infections Clinical Trial
Official title:
Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1
The main objective of the research will be to analyze, through surface electromyography, the impact of inspiratory muscle training before a supervised home training protocol in patients with human T-cell lymphotropic virus type 1 (HTLV-1). For this, a clinical, longitudinal, prospective, quantitative and single center trial will be carried out, aiming at home inspiratory muscle training lasting 5 weeks, 3 times a week, 30 minutes daily through the IMT Threshold, with 14 volunteers enrolled in the Laboratory of Studies in Functional Rehabilitation (LAERF) of the Federal University of Pará (UFPA). They will be classified as the manifestation of Tropical Spastic Paraparesis / Myelopathy (PET / MAH) for GP (PET / MAH probable) and GD (PET / MAH definitive) groups, obeying inclusion criteria. For characterization of expiratory flow rates and flows, as well as respiratory muscle strength, they will be submitted to spirometry and manovacuometry, pre, per, and post treatment, respectively. For the analysis of the electromyographic activity, the diaphragm, parasternal and sternocleidomastoid muscles will be counted in the follow-up during the analysis of inspiratory muscle strength, as well as once a week during the conduction of the inspiratory muscle training protocol. The collected data will be stored in a Microsoft Office Excel® 2010 worksheet and then submitted to statistical analysis using the Bioestat 5.0® program, adopting a standard error of 5%. The theoretical support of the research will have a bibliographical survey of scientific articles collected during the design of the project, and the accomplishment of the research. It is expected to map, through the surface electromyographic study, the impact of respiratory muscle training at a distance on the inspiratory muscle strength of patients with HTLV-I virus with probable or definitive PET / MAH.
Human T-lymphotropic viruses, HTLV (Human Lymphotrophic Virus T), are retroviruses, which
stand out as type 1 (HTLV-1) and type 2 (HTLV-2), the former being the etiologic agent of
serious organ diseases such as leukemia adult T-cell lymphoma (ATLL), a neurological
disorder, Tropical Spastic Paraparesis / HTLV-I-associated myelopathy (PET / HAM) and other
non-malignant ophthalmologic, dermatological, rheumatic and osteomyelitis non-malignant
disorders. For HTLV-2 it has not yet separated with some disease.
The highest prevalence of virus is found in countries of the Caribbean, South America,
Melanesia Islands, West Africa and Japan. Brazil is an endemic country for infection and
prevalence varies from state to state, being highest in Bahia, Pernambuco and Pará. The form
of sexual transmission, hematologic for blood transfusions or accompanied by contaminated
needles, mother-to-child verticalization, the passage of the lymphocyte infected by breast
milk and also in the perinatal period.
The mechanism of the disease comes from the infection of several types of cells, such as T
and B lymphocytes, monocytes and fibroblasts. However, its tropism is by TCD4 + cells. The
form of contamination is cell-cell, thus being transferred from infected material to
uninfected cells, modifying the immune system, as well as cell cells.
The main characteristic of HTLV infection is that in most cases the virus persists
asymptomatic and undetectable by the immune system per year or until death in about 98% of
the patients, while the hosts are able to transmit the virus. There are still no basic
surveys on how severe forms of symptoms of graves occur in those infected.
In this context, when the individual becomes symptomatic, he is affected by chronic infection
that may be associated with disabling diseases that compromise quality of life, such as the
neurological disease PET-MAH. The onset is insidious with frequent changes in gait and
urinary symptoms, mainly affecting the lower limbs such as spasticity, hyperreflexia,
sensory-motor dysfunctions such as neuropathic or nociceptive pain, paresis, paralysis and
paresthesia, urinary bladder disorders, muscle weakness and low back pain. The early
diagnosis of motor complications in the face of the onset of neurological disease also
contributes to the prevention of the installation of motor sensory sequelae if the
physiotherapeutic treatment is established early. According to this reference, one of the
aspects of preventive care refers to the functional autonomy correlated with physical
conditioning in order to increase the strength and / or endurance of the skeletal muscles.
In this way, the possibility of morphological and functional changes in the respiratory
system is also highlighted. With preventive therapeutic possibilities, the respiratory muscle
training (TMR) appears to this indicator with reference to the maximum inspiratory and
expiratory pressures (PiMáx and PeMáx). This procedure directly reflects on the patient's
functionality, having as guideline the conduction of training protocols. The protocol should
be conducted at least three days weekly frequently twice daily.
One tool to evaluate muscular behavior during TMR is surface electromyography (EMGs), which
consists of a non-invasive detection of the muscular electrical activity by which it is
presented graphically. It is constituted by the transcription of the sum of the electrical
activity of all the active muscle fibers, through the positioning of electrodes on the skin.
Thus, in order to verify the muscular activity of the respiratory dynamics related to
inspiration, the main groups are the diaphragm, parasternal intercostal, sternocleidomastoid,
abdominal rectus.
Therefore, the training requires time, availability and greater displacement of the patient
to the outpatient treatment units, thus causing difficulties in adherence to the proposed
therapy. To that end, it has been proposed ways that facilitate such conduction, such as home
treatments, which, in most cases, the patient is supervised by the physiotherapist at least
once a week presently followed by distance monitoring.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT01467024 -
Evaluation of the MP Diagnostics HTLV Blot 2.4
|
N/A | |
Completed |
NCT01754311 -
Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1
|
||
Completed |
NCT03146013 -
Dual Algorithm Post Market Clinical Study
|
N/A | |
Completed |
NCT02655471 -
Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
|
Early Phase 1 | |
Completed |
NCT03226119 -
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
|
Phase 4 |